Keefe Brian
Department of Psychiatry and Behavioral Sciences, University of South Florida, MDC-14, Tampa, FL 33613, USA.
Curr Psychiatry Rep. 2007 Jun;9(3):255-61. doi: 10.1007/s11920-007-0028-4.
Hepatitis C is a global epidemic, and its costs in both lives and health care expenditures continue to rise. The only approved treatment for this disease, interferon-alpha (IFN), causes treatment-emergent depression in more than one quarter of all patients who take it. Newer preparations of IFN have been developed to increase its antiviral efficacy, but the incidence of treatment-emergent depression has not decreased. The data on the epidemiology and risk factors for interferon-induced depression are reviewed in an effort to delineate its standing as a unique psychiatric disorder. In addition, evidence-based treatment approaches are outlined, including the potential efficacy of preinterferon prophylactic treatment with antidepressants.
丙型肝炎是一种全球性流行病,其在生命和医疗保健支出方面的代价持续攀升。针对这种疾病唯一获批的治疗药物——α干扰素(IFN),会使超过四分之一服用该药的患者出现治疗引发的抑郁症。已研发出新型IFN制剂以提高其抗病毒疗效,但治疗引发的抑郁症发病率并未降低。本文回顾了关于干扰素诱发抑郁症的流行病学和风险因素的数据,以明确其作为一种独特精神障碍的地位。此外,还概述了基于证据的治疗方法,包括使用抗抑郁药进行干扰素治疗前预防性治疗的潜在疗效。